IROMED GROUP MANUFACTURES AN INNOVATIVE CXL PRODUCT LINE, CHARACTERIZED BY THE MAXIMUM FLEXIBILITY, IN BOTH APPLICATIONS AND PROTOCOLS.
Causes of the disease are still unclear but is scientifically proven that it involves collagen fibers degradation, which leads to the loss of intramolecular bonds. Those phenomena of thinning and deformation have a faster evolution at a young age and may progress for the entire life. In advanced keratoconus stages, the apex of the corneal cone can become opaque and, rarely, perforate. Corneal deformation can cause irregular astigmatism, usually myopic, with progressive and invalidating visual loss, not easily corrected by glasses or contact lenses.
Corneal Cross-linking (CXL) is a para-surgical technique born in Dresden in 1998. It consists of a photodynamical polymerization of the corneal stroma, to increase its strength by multiplying collagen fibers, with the goal of stabilizing the cornea and stop keratoconus’ progression. CXL is performed using a riboflavin based solution (vitamin B2) combined with an ultraviolet light source (UV-A).
Cross-linking increases and strengthens collagen fibers bonds, stiffening corneal tissues, and halting the ectasic progression. Many clinical and experimental studies demonstrated a significant increase in corneal stiffness after CXL. The technique can be performed with (CXL EPI-OFF) or without corneal epithelium removal (CXL EPI-ON).
Iromed Group manufactures an innovative CXL product line, characterized by the maximum flexibility, in terms of both applications and protocols. All Iromed products are CE Medical Devices and patented.
Raffaella Broccardo | [email protected]
Marco Maria Fedeli | [email protected]
Edoardo Menna | [email protected]
Tel. +39 337 113 84 07
Rosaria Tremamunno | [email protected]
Tel. +39 348 991 4487
Andrea Napolitano | [email protected]
Tel. +39 329 4757978
Carmine Pontecorvo | [email protected]
Fabrizio Pieralisi | [email protected]